drugset / Trial / NCT04381091

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

NCT04381091

Expanded access No longer available Santhera Pharmaceuticals

Summary

Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Idebenone Small molecule 900 mg Oral